Drugs / Q/LAIV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01091246 | Mar → Jul 2010 | — | MedImmune LLC | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Q/LAIV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01091246 ↗ |
| Known as | MEDI3250 | “Q/LAIV (quadrivalent live attenuated influenza vaccine) (MEDI3250) was supplied in the Becton Dickinson Accuspray device that delivers a 0.2 mL total volume intranasal dose...” NCT01091246 ↗ |
| Modality | Vaccine | “quadrivalent live attenuated influenza vaccine” NCT01091246 ↗ |
| Route | Intranasal | “intranasal dose” NCT01091246 ↗ |